GSK5458514 for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expansion phase).
Are You a Good Fit for This Trial?
Men 18 or older with advanced prostate cancer that's resistant to hormone therapy and has spread. They must have tried at least one anti-androgen therapy and up to two chemo treatments. Participants need a confirmed diagnosis, measurable disease, and agree to contraception if sexually active.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive escalating doses of GSK5458514 to determine the maximum tolerated dose
Dose Expansion
Participants receive GSK5458514 at the determined dose to further evaluate safety and efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- GSK5458514
Find a Clinic Near You
Who Is Running the Clinical Trial?
GlaxoSmithKline
Lead Sponsor
Dame Emma Walmsley
GlaxoSmithKline
Chief Executive Officer since 2017
MA in Classics and Modern Languages from Oxford University
Dr. Hal Barron
GlaxoSmithKline
Chief Medical Officer since 2018
MD from Harvard Medical School